dc.contributor
[Giner Soriano M, Gomez Lumbreras A, Ouchi D] Fundació Institut Universitari per a la Recerca a L’Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain. Universitat Autònoma de Barcelona (UAB), Bellaterra, Spain. [Vedia C] Unitat de Farmàcia, Servei d’Atenció Primària Barcelonès Nord i Maresme, Institut Català de la Salut (ICS), Badalona, Spain. Departament de Farmacologia, Terapèutica i Toxicologia, Universitat Autònoma de Barcelona (UAB), Bellaterra, Spain. [Morros R] Fundació Institut Universitari per a la Recerca a L’Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain. Departament de Farmacologia, Terapèutica i Toxicologia, Universitat Autònoma de Barcelona (UAB), Bellaterra, Spain. Institut Català de la Salut (ICS), Barcelona, Spain. Plataforma SCReN, UICEC IDIAP Jordi Gol, Barcelona, Spain
dc.contributor
IDIAP Jordi Gol
dc.contributor.author
Morros, Rosa
dc.contributor.author
Giner-Soriano, Maria
dc.contributor.author
Gomez-Lumbreras, Ainhoa
dc.contributor.author
Ouchi, Dan
dc.contributor.author
Vedia Urgell, Cristina
dc.date.accessioned
2025-10-24T10:58:09Z
dc.date.available
2025-10-24T10:58:09Z
dc.date.issued
2022-06-10T08:50:08Z
dc.date.issued
2022-06-10T08:50:08Z
dc.date.issued
2022-06-08
dc.identifier
Giner‑Soriano M, Gomez‑Lumbreras A, Vedia C, Ouchi D, Morros R. Risk of thrombotic events and other complications in anticoagulant users infected with SARS-CoV-2: an observational cohort study in primary health care in SIDIAP (Catalonia, Spain). BMC Prim Care. 2022 Jun 8;23(1):147.
dc.identifier
https://hdl.handle.net/11351/7659
dc.identifier
10.1186/s12875-022-01752-5
dc.identifier.uri
https://hdl.handle.net/11351/7659
dc.description.abstract
COVID-19; Anticoagulants orals; Esdeveniments trombòtics; Atenció primària
dc.description.abstract
COVID-19; Oral anticoagulants; Thrombotic events; Primary health care
dc.description.abstract
COVID-19; Anticoagulantes orales; Eventos trombóticos; Atención primaria
dc.description.abstract
Background: The risk of thromboembolic events and COVID-19 complications in anticoagulated patients once hos‑
pitalized has been widely analyzed. We aim to assess these outcomes in primary health care (PHC) patients chronically
treated with oral anticoagulants (OAC) in comparison with non-treated.
Methods: Cohort study including adults with COVID-19 diagnosis in the PHC records in Catalonia, Spain; from March
to June 2020. Patients were matched between exposed and non-exposed to OAC based on age and gender in a 1:2
design. Data source is the Information System for Research in Primary Care (SIDIAP).
Results: We included 311,542 individuals with COVID-19. After propensity score matching, we obtained a cohort of
20,360 people, 10,180 exposed and 10,180 non-exposed to OAC. Their mean age was 79.9 and 52.1% were women.
Patients exposed to OAC had a higher frequency of comorbidities than non-exposed. Anticoagulated patients had
a higher risk of hospital admission (IRR 1.16, 95% CI 1.03–1.29), and of stroke and pulmonary embolism than nonanticoagulated (IRR 1,80, 95% CI 1.06–3.06). The risk of pneumonia was not diferent between groups (IRR 1.04, 95% CI
0.84–1.30). We found a lower risk of death in patients exposed to OAC (IRR 0.60, 95% CI 0.55–0.65).
Conclusions: OAC users in our study had more comorbidities and were older than non-users, well known risks for
hospitalization being confrmed with our results. We also found in our study that OAC exposure was not associated
to an increased risk in the mortality rate, and it was associated with higher risks of hospital admission and thrombo‑
embolic events, although we cannot assess the efect of the interventions applied during hospital admission on the
outcomes studied, as our database is a PHC database.
dc.format
application/pdf
dc.publisher
Springer Nature
dc.relation
BMC Primary Care;23(1)
dc.relation
https://doi.org/10.1186/s12875-022-01752-5
dc.relation
EUPAS Register: EUPAS37205
dc.rights
Attribution 4.0 International
dc.rights
https://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Farmacoepidemiologia
dc.subject
Anticoagulants (Medicina) - Efectes secundaris
dc.subject
COVID-19 (Malaltia)
dc.subject
DISCIPLINES AND OCCUPATIONS::Natural Science Disciplines::Biological Science Disciplines::Pharmacology::Pharmacoepidemiology
dc.subject
CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Hematologic Agents::Anticoagulants
dc.subject
DISEASES::Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections
dc.subject
DISCIPLINAS Y OCUPACIONES::disciplinas de las ciencias naturales::disciplinas de las ciencias biológicas::farmacología::farmacoepidemiología
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::fármacos hematológicos::anticoagulantes
dc.subject
ENFERMEDADES::virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus
dc.title
Risk of thrombotic events and other complications in anticoagulant users infected with SARS‑CoV‑2: an observational cohort study in primary health care in SIDIAP (Catalonia, Spain)
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion